We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Medtronic (MDT - Free Report) ended the recent trading session at $97.70, demonstrating a +2.33% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.01%. Meanwhile, the Dow gained 0.51%, and the Nasdaq, a tech-heavy index, lost 0.28%.
Coming into today, shares of the medical device company had gained 2.83% in the past month. In that same time, the Medical sector gained 4.67%, while the S&P 500 gained 4.83%.
Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 18, 2025. The company is forecasted to report an EPS of $1.31, showcasing a 3.97% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $8.84 billion, up 5.26% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.62 per share and revenue of $35.83 billion, indicating changes of +2.37% and +6.82%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Medtronic is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Medtronic is holding a Forward P/E ratio of 17. For comparison, its industry has an average Forward P/E of 18.31, which means Medtronic is trading at a discount to the group.
One should further note that MDT currently holds a PEG ratio of 2.51. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.27 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know
Medtronic (MDT - Free Report) ended the recent trading session at $97.70, demonstrating a +2.33% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.01%. Meanwhile, the Dow gained 0.51%, and the Nasdaq, a tech-heavy index, lost 0.28%.
Coming into today, shares of the medical device company had gained 2.83% in the past month. In that same time, the Medical sector gained 4.67%, while the S&P 500 gained 4.83%.
Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 18, 2025. The company is forecasted to report an EPS of $1.31, showcasing a 3.97% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $8.84 billion, up 5.26% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.62 per share and revenue of $35.83 billion, indicating changes of +2.37% and +6.82%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Medtronic is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Medtronic is holding a Forward P/E ratio of 17. For comparison, its industry has an average Forward P/E of 18.31, which means Medtronic is trading at a discount to the group.
One should further note that MDT currently holds a PEG ratio of 2.51. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.27 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.